Todos Medical Ltd. announced that its academic partner, Dr. Thomas Arendt at Leipzig University, has completed full enrollment for 2nd cohort (confirmatory) for the ongoing clinical trial to evaluate the concordance of the LymPro Alzheimer's Blood Test scores with amyloid PET imaging scores. The Company expects the data to be released in the summer of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | -99.50% |
1st Jan change | Capi. | |
---|---|---|
-99.50% | 3.32K | |
-27.67% | 9.87B | |
-17.30% | 2.74B | |
-11.15% | 2.24B | |
-22.32% | 1.63B | |
+59.69% | 1.39B | |
+23.58% | 772M | |
-1.31% | 760M | |
-28.57% | 516M | |
+5.37% | 310M |
- Stock Market
- Equities
- TOMDF Stock
- News Todos Medical Ltd.
- Todos Medical, Ltd. Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial Vs. Amyloid PET